STOCKS TELEGRAPH

Tag: HURA Stock

  • After-Hour Momentum Builds For TuHURA Biosciences (HURA) Following Merger News

    After-Hour Momentum Builds For TuHURA Biosciences (HURA) Following Merger News

    TuHURA Biosciences, Inc. (NASDAQ: HURA) had a notable surge in its shares during Monday’s extended session, closing at $3.04 after jumping 20.16%. Following the news of a completed merger agreement with Kineta, Inc., which was well received by both companies’ investors at their respective Special Meetings, the rally took place.

    Shareholder Approvals and Strategic Reincorporation

    All proposals, including one to expand the company’s authorized shares to 200 million and another to re-incorporate in Delaware, were approved by TuHURA shareholders at the Special Meeting of Stockholders. Likewise, the planned merger was approved by Kineta investors. According to the firms, if the remaining requirements are met or waived, the deal would be completed soon.

    The FDA Approves the Phase 3 Clinical Trial

    The U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on TuHURA’s Phase 3 study for IFx-2.0 due to manufacturing concerns. This is a separate but strategically connected event. The clearance allows the company to proceed with site activation and trial initiation under the previously agreed Special Protocol Assessment (SPA) with the FDA.

    Milestone-Linked Funding Secured for Trial Progress

    The removal of the FDA hold also marked the fulfillment of the second milestone tied to TuHURA’s recent private placement, unlocking an additional $2.23 million in funding. When used as a first-line therapy for patients with advanced or metastatic Merkel cell carcinoma (MCC), the Phase 3 study will assess IFx-2.0 in addition to Keytruda. About 118 participants from 22 to 25 clinical sites in the US will be a part of the experiment.

    Focus on Efficacy and Safety Endpoints

    Overall Response Rate (ORR) is the study’s main outcome, and safety, response length, overall survival, and progression free survival (PFS) are important secondary outcomes. While positive PFS results without sacrificing overall survival might remove the necessity for a confirmatory post-approval study and open the door to normal approval, success in the ORR measure could result in expedited approval.

  • TuHURA (HURA) Achieves Milestone With FDA Collaboration

    TuHURA (HURA) Achieves Milestone With FDA Collaboration

    TuHURA Biosciences, Inc. (NASDAQ: HURA) experienced a significant stock price surge of 44.70%, closing at $5.05. This rise followed the company’s announcement of substantial progress in achieving its 2024 corporate goals.

    Key Milestones in Clinical Advancements

    Central to these advancements is TuHURA’s collaboration with the FDA’s Oncology Center of Excellence (OCE) and Project Front Runner initiative, culminating in a Special Protocol Assessment (SPA) agreement for a novel Phase 3 trial design for its IFx-2.0 therapy.

    The trial, targeting accelerated approval, emphasizes Overall Response Rate (ORR) as its primary endpoint while incorporating Progression-Free Survival (PFS) as a key secondary endpoint. Achieving this could satisfy requirements for a post-approval confirmatory trial, potentially transitioning the therapy from accelerated to full approval.

    Pipeline Expansion and Strategic Collaborations

    TuHURA is advancing its portfolio with the potential acquisition of KVA12123, a Phase 2-ready VISTA inhibiting antibody, through a non-binding letter of intent with Kineta, Inc. This acquisition aims to integrate therapeutic synergies across TuHURA’s pipeline, bolstering its position as a NASDAQ-listed entity.

    Capital raised earlier in the year is expected to support these programs through late 2025. The company’s IFx technology represents a groundbreaking approach by leveraging proprietary plasmid DNA or mRNA to express bacterial protein Emm55 on tumor surfaces.

    This makes tumors resemble gram-positive bacteria, triggering an immune response via toll-like receptor (TLR) recognition, particularly through TLR2 activation. The resultant activation of antigen-presenting cells (APCs) and tumor-specific adaptive immune responses underscores the therapy’s potential to overcome resistance to checkpoint inhibitors.

    Innovative Approaches to Cancer Treatment

    TuHURA is also advancing Delta receptor technology, focusing on bi-specific immune-modulating ADCs or PDCs. These innovations aim to target myeloid-derived suppressor cells (MDSCs) to counteract immune suppression within the tumor microenvironment, reducing T-cell exhaustion and resistance to cellular therapies.

    Future Prospects

    The FDA has encouraged TuHURA to integrate clinically beneficial secondary endpoints like PFS into its trial designs, aligning with Project Front Runner’s mission to develop cancer treatments for earlier clinical settings. As negotiations with Kineta progress, TuHURA’s efforts in innovation and strategic collaboration position the company as a transformative force in oncology therapeutics.